Introduction
Pelvic organ prolapse is the symptomatic descent of one or more of the anterior vaginal wall, posterior vaginal wall, the uterus (cervix), or the apex of the vagina from the normal anatomical position, 1 caused by herniation through deficient pelvic fascia, or weaknesses or deficiencies in the ligaments or muscles which should support the pelvic organs. Associated symptoms include a sensation of vaginal bulge, something coming down, urinary, bowel and sexual dysfunction, and backache. In one study of 27,000 post-menopausal women, 40% had some degree of prolapse. 2 A woman's lifetime risk of undergoing surgery for prolapse or related urinary incontinence has been estimated as 7% and 11%. 3 In 2012-13 in England, 35,094 women were admitted to hospital with a main diagnosis of female genital prolapse with 29,618 operations performed 4 .
Pelvic floor muscle training (PFMT) is often recommended for prolapse treatment, and theoretically may prevent prolapse progressing and becoming symptomatic. Borello-France 5 found women with stage II prolapse (within +/-1 cm of the hymen) were better able to elevate their pelvic floor than those with stage III or IV prolapse, and hypothesised that weak pelvic floor muscles (PFMs) may be a contributory factor in preventing prolapse development. However the lack of trials evaluating the role of PFMT in prolapse prevention has been highlighted. 6 Conversely clear evidence of the clinical and cost-effectiveness of PFMT in the treatment of established prolapse is now available from two recent randomised controlled trials (RCT). 7, 8 PREVPROL, a secondary prevention trial, 9 aimed to determine clinical and cost-effectiveness of PFMT to prevent prolapse symptoms, worsening prolapse severity and uptake of prolapse treatment. This paper specifically reports symptoms and uptake of treatment in the first two years. We plan to report longer-term outcomes, including prolapse severity, when data become available.
Methods

Study design and participants
This was a three-centre (Dunedin New Zealand, Aberdeen and Birmingham UK), parallel-group RCT (1:1 allocation) of PFMT versus control (prolapse lifestyle advice leaflet) in the secondary prevention of prolapse. Participants had been involved in a longitudinal study of women after an index birth occurring between October 1993 to September 1994 (ProLong). 10 At 12 year follow-up these women were invited to have a POP-Q (Pelvic Organ Prolapse Quantification) examination to assess for prolapse. 11 Women with anatomical evidence of prolapse (POP-Q stage ≥ I), who had not sought prolapse treatment were potentially eligible. Women were excluded if they had stage 0 or IV prolapse; previous incontinence surgery (except mid-urethral sling operation); previous formal instruction in PFMT for any diagnosis in preceding five years; were planning pregnancy, pregnant, or delivered a baby within the last six months; or unable to give informed consent.
Recruitment to the trial focused on those women who had agreed to have a POP-Q at 12 year follow-up in ProLong. In New Zealand (NZ), all such women were asked to complete a baseline questionnaire and, if eligible on the basis of their response, to attend for a further POP-Q. In the UK, it was not feasible to undertake a further POP-Q for every woman, therefore we used the 12 year POP-Q findings and baseline questionnaire responses to confirm eligibility. A small number of UK women who agreed to a POP-Q, but had not been examined at 12 years, were invited for POP-Q assessment if they were eligible based on their baseline questionnaire responses. POP-Qs were carried out in Aberdeen by authors CG and CH, and a nurse and physiotherapist trained to competency by CG; in Birmingham by author PTH, one other experienced urogynaecologist and a POP-Q-trained urogynaecology trainee; and in NZ by author DW and two other gynaecologists trained to competency by DW.
Randomisation and blinding
Group allocation was generated by a researcher using a password-protected computer program at the Trial Office. Group allocation used minimisation based on: centre, parity (≤3 deliveries versus >3), prolapse stage (above hymen versus at/beyond hymen), and delivery method (any vaginal versus all Caesarean Sections). Women were informed of their group by letter. Treatment could not be concealed from women as the intervention involved attendance at appointments and classes, and daily home exercises. Outcome assessment was by participant-completed postal questionnaires administered at baseline (when randomised), one and two years after randomisation. Researchers conducting data entry were blinded to group allocation. Analysis was conducted by a statistician (AE) blinded to group allocation until after the database was closed.
Procedures
The intervention consisted of PFMT delivered both one-to-one and in a class setting. Women were offered five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks (weeks 0, 2, 6, 11 and 16), who assessed pelvic floor muscles, taught correct exercise technique, prescribed individualised home PFMT programme (three sets of exercises daily, completion of exercise diaries), provided a prolapse lifestyle advice leaflet (focusing on weight loss, avoidance of heavy lifting, constipation, coughing, and high-impact exercise), and tailored lifestyle advice (Phase 1). Intervention group women were then offered modified Pilates classes (with pelvic floor muscle exercises as a key distinct element and an exercise DVD 12 for home use), and a one-to-one physiotherapy review appointment one and two years after randomisation (Phase 2). Classes were led by specialist women's health physiotherapists trained in Pilates and took place in six-week blocks; each woman was offered two blocks. In NZ, women were offered attendance at existing weekly Pilates exercise classes, led by physiotherapists similarly trained to those in the UK, at the University of Otago School of Physiotherapy clinics, open also to women in the general public.
Control group women received, by post, the same prolapse lifestyle advice leaflet as the intervention group.
All adverse and serious adverse events were recorded on an Adverse Event Form and reported immediately to the Trial Office in terms of seriousness, relatedness to the intervention and any changes made to the treatment.
The primary outcome was prolapse symptom severity (Pelvic Organ Prolapse Symptom Score, POP-SS) 13 at two years. POP-SS is a validated, patient-completed questionnaire with seven items addressing frequency of prolapse symptoms in the previous four weeks; each item is scored from 0 (never) to 4 (all of the time), with a total ranging from 0-28. Secondary outcomes were prolapserelated quality of life (single item measures scored 0-10, adapted from the International Consultation on Incontinence Questionnaire-Vaginal Symptoms (ICIQ-VS) 14 ); and use of primary and secondary care health services for prolapse symptoms. Other outcomes were self-reported health and well-being using a 12-item short form survey (SF-12) 15 ; lifestyle changes 8 ; urinary leakage (including ICIQ-Urinary Incontinence (ICIQ-UI) short-form 16 , ranging from 0-21, higher score indicating greater severity), bowel symptoms (ICIQ-Bowel Symptoms -early short-form version), sexual symptoms (including the short-form Prolapse Incontinence Sexual Questionnaire (PISQ-12) 17 , ranging from 0-48, higher scores indicating greater sexual dysfunction); PFM exercise adherence; and a rating of health benefit (better, same, worse).
Sample size calculations indicated that 200 per group would provide over 99% power at a 5% significance level (two-sided) to detect a difference of 3 in POP-SS scores (standard deviation of 7 assumed) between groups. This was based on the difference observed in our pilot trial of PFMT for treatment of prolapse. 18 allowing for 10% loss to follow-up.
Statistical analysis
Participants with follow-up data were included in the analysis according to the group to which they had been randomised, whether or not they received their allocated intervention. POP-SS scores were compared using repeated measures mixed models with compound symmetry covariance matrices. Other continuous outcomes were analysed using analysis of covariance, and binary/ordinal outcomes were analysed using binary/ordinal logistic regression. All analyses adjusted for age, minimisation variables and baseline measurements. Assumptions of linearity and normality of error distributions were examined by inspection of residual plots in the mixed models and analyses of covariance, and score tests were performed to examine the proportional odds assumptions in the ordinal models. These assumptions were shown to hold.
Sensitivity analyses were conducted to examine the effect of missing POP-SS data under various assumptions. We first assumed that missing data were missing at random using multiple imputation, with subsequent assumptions that data were missing not at random. Missing data were assumed to be better than expected (one point lower than the imputed value assuming missing at random, and similarly one point worse than expected. We also restricted these assumptions of being better and worse to each arm individually.
Sub-group analyses of treatment interactions with age (<50/50 years+), prolapse stage (above or at the hymen/beyond hymen) 19 , and leading edge of prolapse (anterior/posterior/both) were undertaken.
In the economic evaluation, the SF-12 data were converted to SF-6D using an algorithm from the University of Sheffield (www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d), to allow the estimation of a preference-based single index measure for health using UK population values. 20 SF-6D scores were averaged and used to calculate the cost per QALY at years one and two. The cost of the intervention was calculated using the Department of Health Reference Costs for 2011/12 (www.gov.uk).
Statistical analysis was conducted, using Stata v13 (StataCorp, College Station, TX, USA).
Role of funding source
Study sponsors had no role in design, data collection, analysis, interpretation, or writing of the report. AE, SH, and MC had access to trial data and all authors had final responsibility for the decision to submit for publication. Baseline characteristics are summarised by randomised group in Table 1 . Ninety-seven percent (399/412) of women had prolapse above or at the level of the hymen (186/412, 45% stage I, 213/412, 52% stage II above or at the hymen).
Results
Between
The return rate of questionnaires was 79% at one year and 84% at two years. In the intervention group 74% of women attended three or more of the five appointments offered, 9% (19) attended no appointments, 44% (88) attended all five (mean 3·5 appointments, SD 1·7), and 65% returned all their home exercise diaries. Attendance rate at annual physiotherapy review appointments was 52% and 45% at year 1 and year 2 respectively, and uptake of classes was 28% and 15% at first and second block respectively. At year 2, 77% of women in the intervention group reported they had done PFM exercises in the last four weeks, which was significantly higher than in the control group (53%) (OR 3·22, 95% CI 1·94-5·32, p<0·001).
Three adverse events were reported; all in the intervention group. One woman had a fall the day before attending a Pilates class, one experienced pain in her tail bone during PFMT, and one experienced shortness of breath and chest pain during PFMT.
Primary outcome measure
There was a significantly lower POP-SS score at two years in the intervention group compared to the control group (mean difference −1·01, 95% CI (−1·70 to −0·33), p=0·004) ( Table 2) , indicating fewer symptoms. The difference at one year was also significant in favour of the intervention group (mean difference −0·98, 95% CI (−1·61 to −0·35), p=0·002) ( Table 2) . Sensitivity analyses to examine the effect of missing POP-SS scores gave estimates of the differences between the groups which were significant and similar to those from the original model, ranging from −1.03 to −0.70 at two years. No significant sub-group interaction effects were found.
Other prolapse-related outcomes
The individual POP-SS symptoms significantly more common in the control group at two years were 'a feeling of something coming down from or in your vagina' and 'a need to strain (push) to empty your bladder' ( Table 3 ). The prevalence of these symptoms tended to decrease over time in the intervention group, but stayed constant in the control group. Overall, the symptom most commonly reported by both groups was 'a feeling that your bowel has not emptied completely' (Table 4 ).
Women in the intervention group were more likely to say they felt a health-related benefit from the study compared to controls (44·2% vs 9·8%, OR=7.0 (95% CI 3.9 to 12.8), p<0·001).
There were no significant differences at two years between groups in quality of life associated with prolapse symptoms in any domain ( Table 5 ).
Further treatment for prolapse symptoms within the 2 year follow-up was less common in the intervention group (5·9% vs 14·4%, OR=0·29 (95% CI 0·12 to 0·71), p=0·007). Specifically, the rate of GP consultations relating to prolapse symptoms was lower in the intervention group (2·9% vs 12·2%, OR=0·19 (95% CI 0·05 to 0·67), p=0·010) ( Table 6 ).
Other secondary outcomes
There was a significant difference at two years in favour of the intervention group for the ICIQ-UI SF score, which combines urine leakage frequency, amount and associated bother (mean difference −0·83, 95% CI −1·44 to −0·22, p=0·008). No significant difference was found however between the groups in the percentage who experienced any urine leakage or severe incontinence at two years, or the number of pads used weekly (Table 7) . Faecal urgency and leakage were not significantly different between groups at two years, but interference associated with bowel symptoms was less in the intervention group (mean difference −0·51 (95% CI −0·96 to −0·06), p=0·026). Sexual symptoms did not differ between groups at two years ( Table 7 ). There were greater lifestyle changes in the intervention group in terms of women reducing heavy lifting, changing the way they exercise and attending exercise classes (Table 8) .
Economic outcomes
Cost per QALY was calculated using only the UK data. Cost of the intervention for year 1 includes cost of five physiotherapy appointments, initial appointment letter, prolapse lifestyle advice leaflet, six Pilates-based classes, and physiotherapy review appointment. It is assumed that each woman attends all appointments and classes. The cost of the intervention was calculated at £519 per year for one woman taking part. The control cost was £1 for the prolapse lifestyle advice leaflet. Thus, at year 1, the incremental cost of the intervention is £518. Taking into account savings due to intervention group women having significantly fewer GP contacts relating to prolapse, the adjusted incremental cost is £514. There were no significant differences between groups in the SF-6D score at 
Discussion
Main findings
The prolapse symptom score was less at two years in women randomised to the PFMT intervention.
The control group mean symptom score had stayed similar over the study time-points, whereas the intervention group score had decreased (indicating fewer symptoms on average). The difference between the groups was one point in the POP-SS, but this was less than the minimal clinically important difference for the POP-SS of 1·5 21 . However this MCID value was derived from data on women having surgery for prolapse, and arguably women who are less symptomatic may value a smaller improvement. This assertion is supported by the fact that women in the intervention group were more likely than controls to say they felt a health-related benefit due to the study. Urinary incontinence severity and interference due to bowel symptoms were also significantly less in the intervention group at two years, suggesting additional clinical benefit was gained. There were no differences in the results by sub-group, suggesting that the woman's age, stage of prolapse and prolapse leading edge did not alter the intervention effect. Economic analysis suggests such an intervention could be cost-effective, although cost per QALY ranged from £21,996 in year 1 to £29,409 in year 2, exceeding NICE-recommended cost-effectiveness threshold of £20,000 (https://www.nice.org.uk/article/pmg6/chapter/7-assessing-cost-effectiveness#/economicevidence-and-guideline-recommendations). However, cost-effectiveness may be increased by future savings from reduced use of healthcare for prolapse symptoms in the intervention group. Further follow-up to determine long-term benefits is planned.
Strengths and limitations
The main strengths of this trial were its size, internationality, and pragmatic efficient design, which utilised an existing cohort of women to identify potentially suitable participants. It provides important evidence relevant to women who are at risk of prolapse, a growing number due to the ageing population. Our trial was also woman-centred, with participant-reported symptoms as the primary outcome.
We included women based on their POP-Q stage and absence of previous prolapse treatment, regardless of whether they reported symptoms on the POP-SS. The combination of POP-Q stage and previous treatment was the most objective way to identify women at risk of prolapse progression, given that there are no normative data for the POP-SS to suggest a threshold which would be considered symptomatic. Twenty percent of participants, distributed equally across groups, had a baseline POP-SS of zero, but had stage I, II or III prolapse and had not sought treatment. A post-hoc sensitivity analysis removing these women increased the intervention effect size slightly but would not change the conclusions of the trial.
The difference between the UK and NZ timing of pre-trial prolapse assessment was a limitation. The majority of UK women had a POP-Q assessment between 25 and 57 months prior to the trial, whilst all NZ women had a POP-Q immediately prior to trial entry. This POP-Q information was used, along with baseline questionnaire responses, to determine trial eligibility. It is possible that a UK woman's stage of prolapse had changed in the intervening period, either improving or getting worse 22 , however, such women should be equally distributed between the two groups due to randomisation.
Moreover, from analysis of the NZ POP-Q data, no woman's prolapse stage changed between the 12
year follow-up time-point and trial entry to either a stage 0 or stage IV, meaning eligibility was not affected, and offering reassurance that this is likely to be true also for UK women.
An unavoidable limitation was the lack of blinding of the women participating. The implications of unmasked participants are that women may have been more positive/negative in their responses in the knowledge that they were in the intervention/control group respectively. However in a prevention trial this is less problematic than in a treatment trial since women recruited are not seeking treatment and therefore may be less likely to feel that they have been disadvantaged by being in the control group. We provided control group women with a prolapse lifestyle advice leaflet which they would not otherwise have received in an attempt to minimise this possibility further.
The intervention group women may have felt they were at an advantage because they knew they were having treatment over and above normal care, and we recognise this may have impacted on their responses. Unfortunately the nature of the intervention makes it impossible to avoid such performance bias.
Interpretation of findings in context of other research
The last decade has seen a growth in the evidence-base relating to PFMT for prolapse, however most trials relate to treatment of established symptomatic prolapse in clinical populations. 23 The largest, high quality trials have found PFMT compared to no treatment is effective in reducing prolapse symptoms in women with stage I to III prolapse. 7, 8 Recently other trials of varying size and quality have compared PFMT with active controls such as lifestyle interventions 24 , Pilates 25 , fitness program 26 , or other forms of PFMT 27, 28, 29 . Again these trials have reported benefits from PFMT, although in some cases the active controls have appeared to do equally well. 24, 25, 29 No trial had targeted prolapse prevention prior to PREVPROL commencing. In 2013, Bø published on 175 primiparous women after vaginal delivery to a singleton infant, selected irrespective of whether they had prolapse signs, randomised to supervised PFMT or written PFMT advice (control). 30 The intervention group attended weekly PFMT classes for four months, and performed home-based exercise, while controls had no supervision. At six months post-partum there was no difference between groups in the prevalence of bulging either inside or outside the vagina, nor in stage II prolapse. Due to the difference in populations between this trial and PREVPROL, the findings are not comparable. In a 2016 trial in 287 primary care older women (mean age 64) with symptomatic mild prolapse (above the hymen), Panman 31 randomised women to PFMT or watchful waiting. Women in the PFMT group were given an explanation of pelvic floor anatomy and dysfunctions, were taught "the Knack" 32 , given lifestyle advice, and had visits with the pelvic physiotherapist weekly initially, then at extended intervals. Home PFMT was recommended three to five times a week, twice or three times each day. Similar to our findings, at two years women in the intervention group improved their symptom score significantly more than those in the watchful waiting group, and were more likely to report overall symptom improvement.
Implementation
Although women in our trial had not been seeking treatment, uptake of PFMT appointments was 91%, around half attended for annual reviews, over half had made at least one lifestyle change to reduce risk of prolapse, and 77% reported undertaking PFM exercises at two years, suggesting willingness to engage with a prevention intervention. Generalisability of the findings is important to consider however, as we might expect lower uptake than that observed in the trial if the intervention was rolled out to women in the general population.
There was lower uptake of the exercise classes (28% Year 1 and 15% Year 2), which were intended to support long-term adherence to PFMT, known to decrease with time. This suggests that the effect of the intervention may be due to its one-to-one components (physiotherapy appointments, prescribed home exercise, and lifestyle discussions). We cannot however say with certainty which part or parts of this complex intervention contributed to the effect observed. This would require further trials targeting individual or combined elements of the intervention.
The optimal "dose" and delivery mode of PFMT for this population is something that requires further research. To reduce the burden for women and costs to the health service we would want to know how much physiotherapist contact and supervision is required to achieve sufficient symptom management and avoidance of more invasive treatments, such as pessaries or surgery.
Conclusions
We provide evidence that PFMT leads to a small, but likely important reduction in prolapse symptoms, in women with stage I to III prolapse who have not previously sought prolapse treatment. Evidence was also found in the intervention group of less urinary incontinence, less interference due to bowel symptoms, and lower uptake of prolapse treatment. This is important information for physiotherapists, gynaecologists, and women generally, to inform decisions about adopting preventive strategies. (word count 3822)
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Research in context
Evidence before this study
The lead author is also author of the Cochrane review of conservative prevention and management We have now identified one trial by Bø, in an early post-natal population of women, selected irrespective of whether they had prolapse, 30 and another by Panman in an older population of women in primary care. 31 The former (judged as low risk for selection, performance, detection, attrition and reporting bias, but unclear for other types of bias) found no benefit at 6 months but was not directly comparable. The latter (judged as low risk for all types of bias), which is more comparable to the current trial found a symptom benefit at 2 years.
Added value of this study
PREVPROL is the largest trial of PFMT for prevention of prolapse and the only one in women with signs of prolapse several years after childbirth. Its results, showing that the intervention had significant symptom benefit, will be added to the Cochrane review currently being updated. Metaanalysis of the primary outcomes from this trial (POP-SS at 2 year follow-up) and the Panman trial 31 (PFDI-20 at 2 year follow-up) indicated a significant symptom benefit (reduced symptom score) for women who had undertaken PFMT (pooled SMD is −0.23 (95% CI −0.40 to −0.07), p=0.005).
Implications of all the available evidence
PFMT can prevent prolapse symptoms at 2 years after intervention and may reduce the uptake of treatment. Therefore women should be recommended to undertake PFMT even before they have bothersome symptoms. We do not know the long-term benefits as yet, but given that PFMT is safe and can be performed easily by most women, this should be encouraged. Provision of one-to-one teaching of PFMT is needed to support women with prolapse prevention. Qualitative research is needed to find out from women's perspectives what format a prevention intervention should take to maximise uptake and benefit.
